Horizontal rectus surgery is successful for Duane syndrome


Performing moderate horizontal rectus surgery in Duane syndrome patients is a simple and effective procedure.

Performing moderate horizontal rectus surgery in Duane syndrome patients is a simple and effective procedure, according to a study in the European Journal of Ophthalmology.

A team headed by Dr Pilar Merino, Department of Ophthalmology, Hospital Gregorio Marañón, Madrid, Spain, included 17 Duane syndrome patients who experienced strabismus surgery between 2000 and 2008.

All patients either had medial rectus recession for esotropic deviation or lateral rectus recession for exotropic deviation. The amount of surgery depended on the angle of deviation and abnormal head posture. A good angle of deviation was defined as less than 10 PD and 5º after surgery was considered a good head turn. Head turn was determined as mild, moderate or severe.

In 12 patients the treatment was successful and in the remaining five cases treatment was unsuccessful. Three patients experienced an under corrected deviation and two patients experienced an overcorrected deviation.

The surgery was considered an overall success and there were no secondary duction limitations. In 33% of the patients the surgery only slightly improved abduction.

Recent Videos
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
Jennifer I. Lim, MD, FARVO, FASRS
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
© 2024 MJH Life Sciences

All rights reserved.